Cancer Drug Prices To Fall By Up To 96% From Tomorrow As Government Caps Margins

 

From tomorrow, Monday 9 November 2026, cancer treatment will become noticeably cheaper for thousands of families across India. The government has capped the trade margin on 137 anti-cancer medicines, and more than 1,000 formulations will carry lower prices from tomorrow. Some medicines will cost less than one-tenth of what they cost today.

What Has Changed

The National Pharmaceutical Pricing Authority (NPPA) has capped the trade margin on 137 non-scheduled anti-cancer medicines at 30 per cent of the maximum retail price, excluding GST. The order, issued on 17 October 2026 under the Drugs (Prices Control) Order, 2013, limits the margin kept by distributors and retailers between the price they pay and the price charged to patients. The revised prices take effect on 9 November 2026. The move follows the recommendations of an expert committee set up by the Directorate General of Health Services under the Ministry of Health and Family Welfare.

How Big Are The Price Cuts

Seventy-six pharmaceutical companies have reported revised prices for 1,225 formulations covering 121 of the medicines. More than 1,000 of those formulations will become cheaper, and 600 brands will see their prices cut by more than half. The largest reported reduction is 96.45 per cent. The government estimates the changes could save patients around Rs 3,502 crore a year, a projection based on sales volumes from April 2025 to March 2026.

Some examples show how steep the falls are. Samtepa, a chemotherapy injection, drops from Rs 80,072 to Rs 7,150 for a 100 mg vial. Palbopro, a breast cancer medicine, falls from Rs 40,421 to Rs 2,720 for 21 capsules. Bryxta, used in several cancers, comes down from Rs 25,995 to Rs 3,318, while a strip of ten Anarzole tablets falls from Rs 696 to Rs 73.

What Stays Expensive

Not every medicine becomes cheaper. The cap controls distribution margins rather than fixing the manufacturer's starting price, so some costly brands remain unchanged. Keytruda, a widely used immunotherapy, stays at Rs 2,16,000 for a 100 mg vial. Around ten to fifteen of the 137 medicines have not yet been launched in India, and the cap will apply to them when they are launched. The price control also covers only the cost of medicines, not the full cost of cancer care, which includes hospital stays, tests and doctor consultations.

How To Check The New Prices

Patients and families can check the revised prices of their medicines on the NPPA website or through the Pharma Sahi Daam mobile application before buying. The regulator has said the list of covered medicines will be updated from time to time, and medicines already priced below the new limit cannot be made more expensive.

For families facing cancer, the cost of medicines is often the heaviest burden after the diagnosis itself. A price cut of this scale will not remove that burden entirely, but for many patients it could mean the difference between continuing treatment and stopping it. The real test now is whether the lower prices reach every pharmacy counter, in every town, from tomorrow.

Should life-saving medicines always have a price cap like this one? Share your view in the comments below.